Controlling a master switch of adipocyte development and insulin sensitivity: Covalent modifications of PPARγ

Adipocytes are highly specialized cells that play a central role in lipid homeostasis and the maintenance of energy balance. Obesity, an excessive accumulation of adipose tissue, is a major risk factor for the development of Type 2 diabetes mellitus (T2DM), cardiovascular disease, and hypertension. A variety of studies suggest that obesity and T2DM can be linked to a breakdown in the regulatory mechanisms that control the expression and transcriptional activity of PPARγ. PPARγ is a nuclear hormone receptor that functions as a master switch in controlling adipocyte differentiation and development. Also important in controlling glucose homeostasis and insulin sensitivity, PPARγ is a ligand-dependent transcription factor that is the functional receptor for the anti-diabetic thiazolidinediones (TZDs). In the last fifteen years, a variety of covalent modifications of PPARγ activity have been identified and studied. These covalent modifications include phosphorylation, ubiquitylation, O-GlcNAcylation and SUMOylation. Covalent modifications of PPARγ represent key regulatory mechanisms that control both PPARγ protein stability and transcriptional activity. A variety of PPARγ transgenic models, including mice heterozygous for PPARγ, have demonstrated the importance of PPARγ expression in glucose homeostasis and insulin resistance. In the following review, we have highlighted the regulation of PPARγ by covalent modifications, the interplay between these interactions and how these post-translational modifications impact metabolic disease states. © 2012 Elsevier B.V

Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes

Interferon-γ (IFNγ) treatment of adipocytes results in a down-regulation of the peroxisome proliferator-activated receptor γ (PPARγ). The decrease in PPARγ expression is mediated by inhibition of PPARγ synthesis and increased degradation of PPARγ. In this study, we demonstrate that both PPARγ1 and PPARγ2 are targeted to the proteasome under basal conditions and that PPARγ1 is more labile than PPARγ2. The IFNγ-induced increase in PPARγ turnover is blocked by proteasome inhibition and is accompanied by an increase in PPARγ-polyubiquitin conjugates. In addition, IFNγ treatment results in the transcriptional activation of PPARγ. Similar to ligand-dependent activation of PPARγ, IFNγ-induced activation was greater in the phosphorylation-deficient S112A form of PPARγ when compared with wild-type PPARγ. Moreover, the inhibition of ERKs 1 and 2 with a MEK inhibitor, U1026, lead to an inhibition in the decay of PPARγ proteins, indicating that serine phosphorylation influences the degradation of PPARγ in fat cells. Our results also demonstrate that the proteasome-dependent degradation of PPARγ does not require nuclear export. Taken together, these results indicate that PPARγ is targeted to the ubiquitin-proteasome pathway for degradation under basal conditions and that IFNγ leads to an increased targeting of PPARγ to the ubiquitin-proteasome system in a process that is affected by ERK-regulated serine phosphorylation of PPARγ proteins

STAT5A promotes adipogenesis in nonprecursor cells and associates with the glucocorticoid receptor during adipocyte differentiation

The differentiation of adipocytes is regulated by the activity of a variety of transcription factors, including peroxidase proliferator-activated receptor (PPAR)-γ and C/EBPα. Our current study demonstrates that ectopic expression of STAT5A, such as that of PPAR-γ and C/EBPα, promotes adipogenesis in two nonprecursor fibroblast cell lines. Using morphologic and biochemical criteria, we have demonstrated that STAT5A and the combination of STAT5A and STAT5B are sufficient to induce the expression of early and late adipogenic markers in BALB/c and NIH-3T3 cells. Yet, the ectopic expression of STAT5B alone does not induce the expression of adipocyte genes, but enhances the induction of these genes in cells also expressing STAT5A. This finding suggests that STAT5A and STAT5B do not function identically in adipocytes. In addition, these studies demonstrate that the phosphorylation of STAT5 proteins may play a role in adipogenesis. Moreover, we have shown that STAT5A is associated with the glucocorticoid receptor during adipogenesis in a highly regulated manner

Control of peroxisome proliferator-activated receptor γ2 stability and activity by SUMOylation

Objective: To determine whether small ubiquitin-related modifier (SUMO)ylation of lysine 107 plays a role in regulating the activity of peroxisome proliferator-activated receptor γ (PPARγ). Research Methods and Procedures: Transient expression of wild-type and K107R-PPARγ2 in the NIH 3T3 fibroblast cell line was carried out in conjunction with half-life studies, luciferase activity assays, and indirect immunofluorescence localization studies. Additional in vitro analysis was carried out using recombinant SUMOylation pathway proteins along with in vitro transcribed and translated wild-type or K107R-PPARγ2 to examine the SUMO-1 modification state of wild-type and SUMO-deficient K107R-PPARγ2. Results: While examining PPARγ2 for potential ubiquitylation sites, we identified a strong consensus site for SUMO modification that contains lysine 107. In vitro, SUMOylation studies showed that lysine 107 of PPARγ2 is a major SUMOylation site and that at least one other SUMOylation site is present in PPARγ. In addition, our results demonstrated that SUMO-1 affects PPARγ stability and transcriptional activity but not the nuclear localization of PPARγ. Discussion: These results indicated that SUMOylation plays a role in regulating PPARγ, both indirectly and directly by modification of lysine 107. Because PPARγ is regulated in numerous animal models of obesity, understanding the covalent modifications of PPARγ may enhance our understanding of the metabolic syndrome. Copyright © 2004 NAASO

Siah2 protein mediates early events in commitment to an adipogenic pathway

© 2016 by The American Society for Biochemistry and Molecular Biology, Inc. Adipose tissue expansion occurs by increasing the size of existing adipocytes or by increasing the number of adipocytes via adipogenesis. Adipose tissue dysfunction in obesity is associated with adipocyte hypertrophy and impaired adipogenesis. We recently demonstrated that deletion of the ubiquitin ligase Siah2 is associated with enlarged adipocytes in lean or obese mice. In this study, we find that adipogenesis is impaired in 3T3-L1 preadipocytes stably transfected with Siah2 shRNA and that overexpression of Siah2 in non-precursor fibroblasts promotes adipogenesis. In the 3T3-L1 model, loss of Siah2 is associated with sustained β-catenin expression post-induction, but depletion of β-catenin only partially restores PPARγ expression and adipocyte formation. Using wild-type and Siah2-/- adipose tissue and adipose stromal vascular cells, we observe that Siah2 influences the expression of several factors that control adipogenesis, including Wnt pathway genes, β-catenin, Zfp432, and Bmp-4. Consistent with increased β-catenin levels in shSiah2 preadipocytes, Wnt10b is elevated in Siah2-/- adipose tissue and remains elevated in Siah2-/- primary stromal cells after addition of the induction mixture. However, addition of BMP-4 to Siah2-/- stromal cells reduces Wnt10b expression, reduces Zfp521 protein levels, and increases expression of Zfp423, a transcriptional regulator of peroxisome proliferator-activated receptor γ expression that controls commitment to adipogenesis and is repressed by Zfp521. These results indicate that Siah2 acts upstream of BMP-4 to regulate factors that control the commitment of adipocyte progenitors to an adipogenic pathway. Our findings reveal an essential role for Siah2 in the early events that signal undifferentiated progenitor cells to become mature adipocytes

Designing a Clinical Study With Dietary Supplements: It\u27s All in the Details

A successful randomized clinical trial of the effect of dietary supplements on a chosen endpoint begins with developing supporting data in preclinical studies while paying attention to easily overlooked details when planning the related clinical trial. In this perspective, we draw on our experience studying the effect of an ethanolic extract from Artemisia dracunculus L. (termed PMI-5011) on glucose homeostasis as a potential therapeutic option in providing resilience to metabolic syndrome (MetS). Decisions on experimental design related to issues ranging from choice of mouse model to dosing levels and route of administration in the preclinical studies will be discussed in terms of translation to the eventual human studies. The more complex considerations in planning the clinical studies present different challenges as these studies progress from testing the safety of the dietary supplement to assessing the effect of the dietary supplement on a predetermined clinical outcome. From the vantage point of hindsight, we will outline potential pitfalls when translating preclinical studies to clinical studies and point out details to address when designing clinical studies of dietary supplements

Fine-Tuning Reception in the Bone: PPARγ and Company

PPARγ plays a central role in the formation of fat. Regulation of PPARγ activity depends on numerous factors ranging from dietary ligands to nuclear hormone coactivators and corepressors to oxygen-sensing mechanisms. In addition, the interplay of PPARγ with other nuclear hormone receptors has implications for the balance between adipogenesis and osteogenesis in mesenchymal stem cells of the bone marrow stroma. This review will explore a range of factors influencing PPARγ activity and how these interactions may affect osteogenesis